Transplant Considerations
Results of a recent study suggest that delaying autologous stem-cell transplantation (ASCT) after immunomodulatory therapy is effective and leads to comparable survival rates as with early transplantation in patients with multiple myeloma (Kumar SK, et al. Cancer. 2012;118:1585-1592). The study results indicate that survival outcomes are not compromised when ASCT is delayed if stem cells are harvested early; however, the study was not randomized and was conducted before the bortezomib era.
Value-Based Care in Myeloma - Transplant Considerations, Transplant Considerations, Multiple Myeloma
Value-Based Care in MyelomaTM (VBM) asked transplant specialist
Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan-Kettering Cancer Center, New York, to discuss his transplant strategy for patients with multiple myeloma, and where the field is heading.
Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan-Kettering Cancer Center, New York, to discuss his transplant strategy for patients with multiple myeloma, and where the field is heading.
Results 1 - 6 of 6